Animal Models to Test Adjuvant Treatment: An Experimental Model of Colon Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
GLOBOCAN Cancer Fact Sheets: Colorectal Cancer [Internet]. [cité 29 mai 2013]. Disponible sur: http://globocan.iarc.fr/factsheets/cancers/colorectal.asp .
Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939–44.
André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.
Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768–74.
Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.
Lucas AS, O’Neil BH, Goldberg RM. A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10:238–44.
Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456–61.
Ychou M, Raoul J-L, Douillard J-Y, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009;20:674–80.
Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27:3117–25.
Chibaudel B, Tournigand C, André T, et al. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:75–89.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.
Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11–6.
•• De Gramont A, Van Cutsem E, Schmoll H-J, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225–33. After the failure of this study, this is definitely the last clinical trial conducted without a prior preclinical study.
Alberts SR, Sargent DJ, Nair S, Mahoney MR, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. J Am Med Assoc. 2012;307:1383–93.
Taieb J, Tabernero J, Mini E, et al. Adjuvant FOLFOX4 with or without cetuximab (CTX) in patients (pts) with resected stage III colon cancer (CC): DFS and OS results and subgroup analyses of the PETACC8 intergroup phase III trial. Annals Oncol. 2012; 23; supplement 3, Late Braking Abstract 4.
Schackert HK, Fidler IJ. Development of an animal model to study the biology of recurrent colorectal cancer originating from mesenteric lymph system metastases. Int J Cancer. 1989;44:177–81.
Ebos JML, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8:210–21.
Bagri A, Kouros-Mehr H, Leong KG, et al. Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends Mol Med. 2010;16:122–32.
• Van Cutsem E, Lambrechts D, Prenen H, et al. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J Clin Oncol. 2011;29:1–4. The authors explain the significance of developing new animal models that accurately replicate the natural history of cancer for testing therapeutic agents in preclinical before clinical trials.
Fidler IJ. The pathogenesis of cancer metastasis: the « seed and soil » hypothesis revisited. Nat Rev Cancer. 2003;3:453–8.
Podsypanina K, Du Y-CN, Jechlinger M, et al. Seeding and propagation of untransformed mouse mammary cells in the lung. Science. 2008;321:1841–4.
Tester AM, Ruangpanit N, Anderson RL, et al. MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial–mesenchymal transition traits. Clin Exp Metastasis. 2000;18:553–60.
Hirayama R, Sato K, Hirokawa K, et al. Different metastatic modes of malignant melanoma implanted in the ear of young and old mice. Cancer Immunol Immunother. 1984;18:209–14.
Hoshida T, Isaka N, Hagendoorn J, et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res. 2006;66:8065–75.
Kozlowski JM, Fidler IJ, Campbell D, et al. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 1984;44:3522–9.
Warren RS, Yuan H, Matli MR, et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995;95:1789–97.
Mordant P, Loriot Y, Lahon B, et al. Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells. PLoS One. 2011;6:e26073.
Pocard M, Tsukui H, Salmon RJ, et al. Efficiency of orthotopic xenograft models for human colon cancers. In Vivo. 1996;10(5):463–9.
House AK, Maley MA. Clinical and in vivo response following surgery or surgery plus adjuvant chemotherapy or immunotherapy for colorectal carcinoma in a rat model. J R Soc Med. 1983;76:833–40.
Singh M, Johnson L. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res. 2006;12:5312–28.
McCart AE, Vickaryous NK, Silver A. Apc mice: models, modifiers and mutants. Pathol Res Pract. 2008;204:479–90.
Eveno C, Contreres J-O, Hainaud P, et al. Netrin-4 overexpression suppresses primary and metastatic colorectal tumor progression. Oncol Rep. 2013;29:73–8.
Cree IA, Glaysher S, Harvey AL. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol. 2010;10:375–9.
Fichtner I, Slisow W, Gill J, et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer. 2004;40:298–307.
Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer. 2004;40:802–20.
Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther. 2009;85:217–21.
Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011;10:1311–6.
Krumbach R, Schüler J, Hofmann M, et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer. 2011;47:1231–43.
Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (« xenopatients ») identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508–23.
DeRose YS, Wang G, Lin Y-C, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17:1514–20.
•• Julien S, Merino-Trigo A, Lacroix L, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res. 2012;18:5314–28. The authors show that use of PDX models is the better way of representing the heterogeneity of human cancers and, above all, of evaluating novel targeted therapeutic strategies.
Cancer Diagnosis - Understanding Cancer - Stanford Cancer Center - Stanford Medicine [Internet]. [cité 29 mai 2013]. Disponible sur: http://cancer.stanford.edu/information/cancerDiagnosis/ .
Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum. 1994;37:272–7.
Nicklas JA, Noreault-Conti T, Buel E. Development of a real-time method to detect DNA degradation in forensic samples. J Forensic Sci. 2012;57:466–71.
Harper K, Arsenault D, Boulay-Jean S, et al. Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation. Cancer Res. 2010;70:4634–43.
Abstract 359: Longitudinal monitoring of autotaxin-expressing tumors in vivo using an activatable near-infrared fluorescent probe—Madan 72 (1008): 359—Cancer Research [Internet]. [cité 29 mai 2013]. Disponible sur: http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/359 .
Némati F, Sastre-Garau X, Laurent C, et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res. 2010;16:2352–62.
Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007;13:3989–98.
Takahashi Y, Ellis LM, Wilson MR, et al. Progressive upregulation of metastasis-related genes in human colon cancer cells implanted into the cecum of nude mice. Oncol Res. 1996;8:163–9.